Intelgenx Technologies Quick Ratio (IGXT) starting from the first quarter 2024 to first quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Intelgenx Technologies Corp   (IGXT)

Intelgenx Technologies 's Quick Ratio

IGXT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2024, Quick Ratio fell to 0.05 a new company low.

Within Major Pharmaceutical Preparations industry 466 other companies have achieved higher Quick Ratio than Intelgenx Technologies in first quarter 2024. While Quick Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 3054 to 3988.

Explain Quick Ratio?
How much Cash & cash equivalents IGXT´s has?
What are IGXT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IGXT Quick Ratio (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1
Y / Y Current Liabilities Change 46.3 % 226.8 % 70.36 % 413.14 % 58.89 %
Y / Y Cash & cash equivalent Change -79.03 % -13.38 % -56.43 % -69 % -61.42 %
Quick Ratio MRQ 0.05 0.4 0.56 0.19 0.36
IGXT's Total Ranking # 3988 # 3054 # 1606 # 2520 #
Seq. Current Liabilities Change 181.55 % 53.72 % -67.09 % 2.73 % 528.91 %
Seq. Cash & cash equivalent Change -64.11 % 9.58 % -3.33 % -44.84 % 48.25 %



Quick Ratio first quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 467
Healthcare Sector # 946
Overall Market # 3988


Quick Ratio Statistics
High Average Low
9.2 2.5 0.05
(Mar 31 2012)   (Mar 31 2024)




Financial Statements
Intelgenx Technologies 's Current Liabilities $ 17 Millions Visit IGXT's Balance sheet
Intelgenx Technologies 's Cash & cash equivalent $ 1 Millions Visit IGXT's Balance sheet
Source of IGXT's Sales Visit IGXT's Sales by Geography


Cumulative Intelgenx Technologies 's Quick Ratio

IGXT's Quick Ratio for the trailling 12 Months

IGXT Quick Ratio

 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth 114.94 % 143.04 % 53 % 9.97 % -35.38 %
Y / Y Cash & cash equivalent TTM Growth -59.84 % -57.43 % -65.99 % -65.23 % -58.24 %
Quick Ratio TTM 0.2 0.33 0.39 0.52 1.07
Total Ranking TTM # 3780 # 3624 # 3817 # 3887 #
Seq. Current Liabilities TTM Growth 16.05 % 14.29 % 5.85 % 53.1 % 31.22 %
Seq. Cash & cash equivalent TTM Growth -29.61 % -3.27 % -20.02 % -26.25 % -25.39 %

Quick ratio ranking by company, industry and sector >> Back to IGXT Financial Strength Comparisons >> Go to Compare IGXT Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q1 2024 to $16.52 millions, cumulative Quick Ratio decreased to 0.2 below the Intelgenx Technologies Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 491 other companies have achieved higher Quick Ratio than Intelgenx Technologies . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 3624 to 3780.

Explain Quick Ratio?
How much Cash & cash equivalents IGXT´s has?
What are IGXT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 492
Healthcare Sector # 1016
Within the Market # 3780


trailing twelve months Quick Ratio Statistics
High Average Low
7.09 2.11 0.23
(June 30. 2014)  




Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2024 MRQ Cash & cash equivalentMar 31 2024 MRQ Current Liabilities
Briacell Therapeutics Corp   0.14 $ 0.936  Millions$ 6.758  Millions
Exicure Inc   0.14 $ 0.366  Millions$ 2.661  Millions
Cns Pharmaceuticals Inc   0.13 $ 0.815  Millions$ 6.091  Millions
Scorpius Holdings inc   0.13 $ 1.684  Millions$ 12.825  Millions
Viatris Inc   0.13 $ 1,014.600  Millions$ 7,759.900  Millions
Gsk Plc  0.13 $ 4,845.627  Millions$ 38,408.167  Millions
Emergent Biosolutions Inc   0.12 $ 78.500  Millions$ 630.200  Millions
Agile Therapeutics Inc  0.12 $ 2.615  Millions$ 21.063  Millions
Alzamend Neuro Inc   0.12 $ 0.376  Millions$ 3.226  Millions
Nrx Pharmaceuticals Inc   0.11 $ 1.319  Millions$ 11.587  Millions
Cv Sciences Inc   0.11 $ 0.662  Millions$ 5.959  Millions
Aeon Biopharma inc   0.10 $ 1.558  Millions$ 15.957  Millions
Takeda Pharmaceutical Company Limited  0.10 $ 3,331.420  Millions$ 34,209.302  Millions
NIKA PHARMACEUTICALS, INC  0.09 $ 0.025  Millions$ 0.266  Millions
Mustang Bio inc   0.09 $ 1.337  Millions$ 15.691  Millions
Lifecore Biomedical Inc   0.08 $ 3.073  Millions$ 36.810  Millions
Dr Reddy s Laboratories Limited  0.07 $ 85.000  Millions$ 1,152.000  Millions
One World Products Inc   0.06 $ 0.126  Millions$ 1.971  Millions
Kazia Therapeutics Limited  0.06 $ 1.106  Millions$ 17.648  Millions
Amneal Pharmaceuticals Inc   0.06 $ 51.617  Millions$ 834.388  Millions
Prophase Labs Inc   0.05 $ 1.233  Millions$ 23.907  Millions
Intelgenx Technologies Corp   0.05 $ 0.846  Millions$ 16.516  Millions
Bio path Holdings inc   0.05 $ 0.188  Millions$ 3.812  Millions
Protokinetix Incorporated  0.04 $ 0.003  Millions$ 0.068  Millions
Northwest Biotherapeutics Inc  0.04 $ 2.478  Millions$ 62.440  Millions
Innovation1 Biotech Inc   0.04 $ 0.108  Millions$ 2.904  Millions
Nexien Biopharma Inc   0.03 $ 0.010  Millions$ 0.340  Millions
Celularity Inc   0.03 $ 1.902  Millions$ 66.044  Millions
Abvc Biopharma Inc   0.03 $ 0.167  Millions$ 6.028  Millions
Emmaus Life Sciences Inc   0.03 $ 1.712  Millions$ 62.428  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.